Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Operations (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Cash from Operations for 9 consecutive years, with 36975000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 26.72% to 36975000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 57671000.0 through Dec 2025, down 68.68% year-over-year, with the annual reading at 57671000.0 for FY2025, 68.68% down from the prior year.
  • Cash from Operations hit 36975000.0 in Q4 2025 for Protagonist Therapeutics, down from 1937000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 268622000.0 in Q2 2024 to a low of 37666000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 2220750.0 across 5 years, with a median of 27184000.0 in 2021.
  • Biggest YoY gain for Cash from Operations was 1123.79% in 2024; the steepest drop was 272.04% in 2024.
  • Year by year, Cash from Operations stood at 26939000.0 in 2021, then fell by 17.43% to 31635000.0 in 2022, then surged by 153.61% to 16960000.0 in 2023, then crashed by 272.04% to 29178000.0 in 2024, then fell by 26.72% to 36975000.0 in 2025.
  • Business Quant data shows Cash from Operations for PTGX at 36975000.0 in Q4 2025, 1937000.0 in Q3 2025, and 28780000.0 in Q2 2025.